Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Technical Presentation (September 2021)
15 slides from Matinas Biopharma's technical presentation, Sep 13, 2021
Slide 1: EnACT Topline Data
MATINAS BIOPHARMA EnACT — Topline Data N September 13, 2021 \ }
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Agenda
Agenda Opening Remarks ¢ Jerome D. Jabbour, Chief Executive Officer Review of Results ¢ Theresa Matkovits, PhD, Chief Development Officer Principal Investigator/KOL Perspective ¢ David Boulware, MD, MPH, FIDSA LNC Platform Implications * James J. Ferguson, MD, Chief Medical Officer Question & Answer
Slide 4: EnACT: Review of Results
MATINAS BIOPHARMA EnACT: Review of Results Theresa Matkovits, PhD Chief Development Officer, \\
Slide 5: Disease Overview and Treatment
Disease Overview and Treatment Cryptococcal Meningitis (CM) = Difficult-to-treat invasive fungal infection impacting the brain and central nervous system = Associated with high mortality Early Treatment Phases (Standard of Care) = Induction (1-2 weeks): IV amphotericin with oral flucytosine (5-FC),
Slide 6: MAT2203
MAT2203: *= Oral amphotericin B formulation utilizing Matinas’ proprietary lipid nanocrystal (LNC) delivery platform = Proprietary formulation with robust intellectual property protection MAT2203 = Initial gateway indication to treat CM with plans to expand use into treatment of other invasive funga
Slide 7: EnACT Treatment Regimens and Cohorts
Induction (2 weeks) v¥ Cohort 1 FAW (n=10) 5 days v Cohort 2 FAW (n=40) 2 days Cohort 3 (n=10) Cohort 4 (n=40) Adjunctive Rx SFC Early Consolidation (4 weeks) (all cohorts) 7 IV AMB = intravenous amphotericin B Fluconazole }——_—_—_> MAT2203 TREATMENT REGIMENS: Cohort 1 + Induction: 2.0g/day * Consol
Slide 8: Design of EnACT and Potential Indications
s of EnACT and Potential Indications = Sequential cohort, gradually extending use of oral MAT2203, to assess safety and efficacy = Strategic design, providing data to support up to three potential indications = Rigorous safety monitoring; DSMB review after each cohort Step-down induction treatment f
Slide 9: EnACT — Baseline and Demography Summary
EnACT — Baseline and Demography Summary = 71 total patients were randomized in Cohorts 1 and 2 = Cohort 1 (MAT2203): 10 patients = Cohort 2 (MAT2203): 40 patients = SOC (combined): 21 patients = Demographic and baseline characteristics were comparable across the treatment groups = First episode of C
Slide 10: EnACT — Efficacy Endpoints and Analyses
EnACT — Efficacy Endpoints and Analyses = Primary Endpoint: EFA (log,, CFU/mL/day) at Day 14 = Rate of CSF fungal clearance (log reduction) = Quantitative measure of antifungal activity of an induction treatment for CM = Early surrogate marker that predicts survival = Primary Endpoint Objective: Dem
Slide 11: EnACT — Efficacy Results for Cohort 2
11 EnACT — Efficacy Results for Cohort 2 Primary endpoint : EFA for MAT2203 treated patients > 0. Key primary and secondary endpoints: 1) EFA: 2) Patients achieving sterile culture while on MAT2203 3) Patients with relapse or breakthrough infections 4) Patient survival” 5) Patients with MAT2203-rela
Slide 12: Cohort 2 — Summary of Overall Safety and Efficacy
rt 2—Summary of Overall Safety and Efficacy Safety Efficacy = MAT2203 was safe and well-tolerated over 6 weeks = EFA for MAT2203 was 0.38 (95% CI 0.30 to 0.46), meeting the of treatment primary endpoint for the study * No renal toxicity or electrolyte abnormalities = Also met major clinical endpoint
Slide 13: EnACT — Principal Investigator/KOL Remarks
EnACT — Principal Investigator/KOL Remarks David Boulware, MD, MPH Dr. Boulware is an infectious disease physician-scientist and Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota Medical School. His primary research interests are in meni
Slide 14: LNC Platform Implications
MATINAS “BIOPHARMA — LNC Platform Implications James J. Ferguson, MD, FACC, FAHA | Chief Medical Officer
Slide 15: Question & Answer Session
MATINAS BIOPHARMA Question & Answer ' Session
Matinas BioPharma Holdings — Technical Presentation (September 2021) on 6ix